Across TCGA pan-cancer cohorts, RNASE10 Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated RNASE10 data layer compared with 21 for mass-spec protein.
The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher RNASE10 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated RNASE10 expression acts as an unfavorable survival marker, although some lineages such as SKCM show a favorable association.
HNSC and SKCM are the cancer types where RNASE10 Mutation most reproducibly stratifies survival.